DDInter262 DDInter1658
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Cabozantinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Cabozantinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Epoprostenol
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Cabozantinib may lead to a major life threatening interaction when taken with Epoprostenol
Cabozantinib may lead to a major life threatening interaction when taken with Troleandomycin
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Cabozantinib may lead to a major life threatening interaction when taken with Flurbiprofen